Cases and resources in vascular techniques
This section provides a selection of cases and resources provided by experts in vascular techniques.
Why do many PAD patients still present too late? Dr Ralf Langhoff shares his perspective on the challenges facing PAD care in Europe and the actions needed to improve awareness, evidence generation and patient outcomes.
Paclitaxel-coated technologies have significantly improved outcomes after femoropopliteal interventions, but concerns over long-term mortality have remained. New evidence from the SWEDEPAD 2 trial has prompted a focused update of the 2024 ESVS Guidelines.
When a femoropopliteal bypass fails, the next step is rarely straightforward. Dr Prakash Krishnan discusses complex endovascular options, emerging technologies and the multidisciplinary decision-making needed to choose the best treatment for each patient.
Previous FEVAR adds complexity to every treatment decision. Analyse this challenging case of a 72-year-old man presenting with non-specific abdominal symptoms, evaluate the available therapeutic options and compare your choice with the authors' strategy.
Could endovascular-first become the next step in acute limb ischaemia care? Dr Zaharudin shares the Malaysian perspective.
Dr Mafalda Massara interviews Prof. Stephan Haulon on the evolving role of endovascular repair for acute type A aortic dissection, discussing patient selection, innovative device concepts and the technical considerations shaping this emerging approach.
Major lower limb amputation rates are falling globally, but this improvement is not evenly shared — with rising incidence still observed in low- and middle-income countries.
In conversation with Dr Gustavo Basso, Prof. Sarah Thomis and Prof. Jorinde van Laanen review the latest evidence on compression therapy after endovenous treatment, pelvic venous disorders and medical treatment following endovenous interventions.
Why was a Delphi consensus needed for femoropopliteal artery disease? In this one-minute interview, Prof. Secemsky explains how expert guidance can help navigate the growing range of endovascular treatment options.
In the prospective FESTIVAL registry, IVL without stenting achieved high patency rates and low reintervention rates in patients with de novo CFA disease. Outcomes were particularly favourable in lesions not involving the femoral bifurcation.
